drugset
drugset / Trial / NCT02668367

Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy Volunteers

NCT02668367 ↗

Phase 1 Completed 36 enrolled Biota Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a single center, sequential-cohort, double-blind, placebo-controlled, multiple ascending dose (MAD), 7-day treatment period study in healthy subjects.

Timeline

Start
2015-11
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator BTA-C585 Unknown 100 mg Oral
Comparator BTA-C585 Unknown 600 mg Oral

Indications

No indication recorded.